Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769–2778. PubMed PMID: 29050646.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Sep 27. PubMed PMID: 31562236. DOI:https://doi.org/10.1136/gutjnl-2019-318484
   Google Scholar
• Selinger CP, Parkes GC, Bassi A, et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Nov;46(10):964–973. PubMed PMID: 28949018.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019 Mar;22(114):874–883. . PubMed PMID: 30908297.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015 Sep;110(9):1324–1338. PubMed PMID: 26303131.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736. PubMed PMID: 28467869.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):215–226. . PubMed PMID: 28099821.
   PubMed Web of Science ®Google Scholar
• Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis – innovative thinking and evolving concepts. Aliment Pharmacol Ther. 2010 Nov;32(9):1051–1058. . PubMed PMID: 20815833; eng.
   PubMed Web of Science ®Google Scholar
• Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008 Apr;53(4):1020–1024. . PubMed PMID: 17934828; eng.
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 Jan;114(1):39–43. [pii]. PubMed PMID: 12543288; eng.
   PubMed Web of Science ®Google Scholar
• Selinger C, Eaden J, Jones B, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(10):2199–2206. .
   PubMed Web of Science ®Google Scholar
• Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 2010 Jan 10;10:1. PubMed PMID: 20064220; PubMed Central PMCID: PMCPMC2817682.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012 Aug;18(8):1523–1530. . PubMed PMID: 21987429.
   PubMed Web of Science ®Google Scholar
• Selinger C, Carbonell J, Kane J, et al. Acceptability of a ‘treat to target’ approach in inflammatory bowel disease to patients in clinical remission. J Frontline Gastroenterol. 2020 flgastro-2019-101366. doi:https://doi.org/10.1136/flgastro-2019-101366
   Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361–370. PubMed PMID: 6880820; eng.
   PubMed Web of Science ®Google Scholar
• Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s relapse prevention trial. Am J Gastroenterol. 1996 Aug;91(8):1571–1578. PubMed PMID: 8759664; eng
   PubMed Web of Science ®Google Scholar
• Horne R, Parham R, Driscoll R, et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009 Jun;15(6):837–844. PubMed PMID: 19107771; eng.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Ochieng AO, George V, et al. The accuracy of adherence self-report scales in patients on thiopurines for inflammatory bowel disease: a comparison with drug metabolite levels and medication possession ratios. Inflamm Bowel Dis. 2018 Sep 27. DOI:https://doi.org/10.1093/ibd/izy309. [ PubMed PMID: 30265299].
   Google Scholar
• Keegan D, McDermott E, Byrne K, et al. Development, validation and clinical assessment of a short questionnaire to assess disease-related knowledge in inflammatory bowel disease patients. Scand J Gastroenterol. 2013 Feb;48(2):183–188. PubMed PMID: 23181503.
   PubMed Web of Science ®Google Scholar
• Labetoulle R, Paul S, Roblin X. Filgotinib for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2018 Mar;27(3):295–300. . PubMed PMID: 29448862.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV Jr., et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020 Jun;158(8):2123–2138e8. PubMed PMID: 32044319.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis. Gastroenterology. 2020 Feb;158(3):550–561. PubMed PMID: 31711921.
   PubMed Web of Science ®Google Scholar
• Corte C, Saxena P, Tattersall S, et al. When to use biological agents in inflammatory bowel disease. J Gastroenterol Hepatol. 2011 Dec. DOI:https://doi.org/10.1111/j.1440-1746.2011.07056.x. PubMed PMID: 22188169; ENG
   Google Scholar
• Kennedy NA, Jones GR, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 Jun;69(6):984–990. PubMed PMID: 32303607; PubMed Central PMCID: PMCPMC7211081.
   PubMed Web of Science ®Google Scholar